Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032).

"Competing interests: MC reports research support from Bristol Myers Squibb; consulting fees from AstraZeneca, Bristol Myers Squibb, ImmunoCore, InCyte, Merck, and Moderna; and is an employee at UConn Health. AA reports support for the present manuscript from Bristol Myers Squibb; honoraria from Bristol Myers Squibb, Merck, and Regeneron; travel/meetings funding from Bristol Myers Squibb, Merck, and Regeneron; and participation in advisory board for Bristol Myers Squibb, Eisai, and Sanofi. FJK reports no conflicts of interest. MM reports support for the present manuscript from Bristol Myers Squibb; and consulting fees and honoraria from Ipsen. MHT reports grants or contracts from Bristol Myers Squibb, Exelixis, Merck, and Pfizer; consulting fees from Array Biopharma, Bayer, Cascade Prodrug, Immune-Onc, Incyte, Merck, Novartis, Pfizer, Regeneron, and Sanofi/Genzyme; honoraria from Blueprint Medicines, Bristol Myers Squibb, Eisai, and Merck; participation in advisory board for Oncosec; and is an employee at Providence Cancer Institute. KP reports support for the present manuscript from Bristol Myers Squibb; consulting fees and honoraria from Bristol Myers Squibb, Lilly, Merck Sharp & Dohme, Pfizer, Novartis, and Ipsen; participation in advisory board for Bristol Myers Squibb, Merck Sharp & Dohme, and Ipsen; owning stocks/stock options from Faron Pharmaceuticals; and other financial/non-financial interests for Bristol Myers Squibb, Lilly, Novartis, Exelixis, Pfizer, Merck Sharp & Dohme, Incyte, Eisai, and Bayer. PS reports participation in advisory board and stock or stock options for Achelois, Adaptive Biotechnologies, Affini-T, Apricity, BioAtla, BioNTech, Candel Therapeutics, Catalio, Codiak, Dragonfly, Earli, Enable Medicine, Glympse, Hummingbird, ImaginAb, Infinity Pharma, JSL Health, Lava Therapeutics, Lytix, Marker, Oncolytics, PBM Capital, Phenomic AI, Polaris Pharma, Sporos, Time Bioventures, Trained Therapeutix, Two Bear Capital, Venn Biosciences. EO’R reports consulting fees from Seagen, Boehringer Ingelheim, BioNTech, Ipsen, Merck, IDEAYA, Novartis, AstraZeneca, BioSapien, Cend Therapeutics, Astellas, Thetis, Autem, Tempus, Agios, Genentech-Roche, and Eisai; and other financial/non-financial interests for Genentech/Roche, Celgene/ Bristol Myers Squibb, BioNTech, AstraZeneca, Arcus, Elicio, Pertzye, Elicio Therapeutics, and Parker Institute. SMS reports owning stocks/stock options and being an employee of Bristol Myers Squibb. SO’B reports being an employee of Bristol Myers Squibb. MT reports owning stocks/stock options and being an employee of Bristol Myers Squibb. DTL reports grants or contracts from Bristol Myers Squibb, Merck, Aduro Biotech, Medivir, Nouscom, Curegenix, and AbbVie; consulting fees from Bristol Myers Squibb, Merck, Nouscom, G1 Therapeutics, Janssen, Merus, and Regeneron; and honoraria from Merck."

"Funding: This study was funded by Bristol Myers Squibb."